Emerald Advisers’s Applied Therapeutics APLT Stock Holding History

Emerald Advisers’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-611,525	Closed	-$5.47M	–	265
2021 Q4	$5.47M	Buy	611,525 +45,797	+8%	+$601K	0.2%	112
2021 Q3	$9.39M	Sell	565,728 -3,335	-0.6%	-$57.6K	0.34%	99
2021 Q2	$11.8M	Buy	569,063 +14,784	+3%	+$280K	0.43%	91
2021 Q1	$10.4M	Buy	554,279 +38,555	+7%	+$832K	0.38%	103
2020 Q4	$11.4M	Buy	515,724 +10,649	+2%	+$222K	0.38%	99
2020 Q3	$10.5M	Buy	505,075 +103,744	+26%	+$2.7M	0.43%	80
2020 Q2	$14.5M	Buy	401,331 +92,378	+30%	+$3.87M	0.63%	60
2020 Q1	$10.1M	Buy	308,953 +281,688	+1,033%	+$11.4M	0.58%	66
2019 Q4	$744K	Buy	27,265 +17,121	+169%	+$293K	0.03%	161
2019 Q3	$111K	Buy	+10,144	New	+$95.7K	0.01%	240

Other funds holding APLT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers's APLT Position: Q1 2022 in Review

Emerald Advisers sold out of Applied Therapeutics (APLT) in Q1 2022, closing a stake of 611,525 shares — an estimated $5.47M sold.

Emerald Advisers first reported a position in APLT in Q3 2019 and held it in 10 quarters. The position peaked at $14.5M in Q2 2020. 71 funds tracked by Wall St. Rank hold APLT as of Q1 2022.

Emerald Advisers reported no remaining Applied Therapeutics position as of Q1 2022 after selling out during the quarter.
Emerald Advisers sold 611,525 Applied Therapeutics shares in Q1 2022, an estimated $5.47M.
Emerald Advisers first reported a position in Applied Therapeutics in Q3 2019 and held it in 10 quarters.
Emerald Advisers's Applied Therapeutics position peaked at $14.5M in Q2 2020.
71 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2022.

Based on Emerald Advisers's 13F filing for Q1 2022, filed 29 Apr 2022.